The focussed and simplified approach implemented by the new management team last year is beginning to pay off. Results are in line with expectations and the outlook is supportive of our (unchanged) estimates. The core Specials business remains stable and cash generative and profitability in Niche Pharma has been transformed. The business is now moving on strongly and recent challenges have been consigned to history. The current share price does not reflect the substantial growth prospects of the ....
